Hematology: Page 2

Quotient Q1 2023 revenues drop on customer order change

For the quarter ended June 30, the Eysins, Switzerland-based firm posted a net loss of $38.9 million, or $.37 per share, compared to $27.3 million, or $.27 per share, in fiscal Q1 2022.

August 8, 2022

Video from AACC: Beckman Coulter partners with Scopio

Dr. Peter Soltani, senior vice president and general manager at Beckman Coulter, and Itai Hayut, cofounder and CEO of Scopio Labs, spoke to LabPulse.com and ScienceBoard.net about the partnership.

July 31, 2022

Smartphone app, blood test may predict clotting risk

The test uses a smartphone's built-in vibration motor and camera to track movement of a copper particle in a drop of blood.

July 25, 2022

Beckman, Scopio to partner on blood smear platforms

Scopio's technology employs full-field imaging and artificial intelligence (AI) decision support with the aim of eliminating manual microscopy. The platform allows full-field images to be shared in real-time over a secure hospital network and captures large scan areas at 100X magnification.

July 19, 2022

Philips adopting proteomics results for patient management

The integration of proteomics results from the blood-based test -- along with the radiologic and patient history data currently used to determine treatment decisions -- can help create diagnostic efficiency for cancer care centers, Philips said.

June 29, 2022

Quotient discloses underwritten public offering price

The company said the aggregate net proceeds to Quotient from this offering are expected to be approximately $18.5 million. The company also offered all of the securities sold. Furthermore, Quotient granted the underwriters a 30-day option to purchase up to an additional 10,000,000 of its ordinary shares. The company said that it plans to use net proceeds to fund the ongoing development and commercialization of its MosaiQ microarray menu. It added that funds will go toward working capital, operating expenses, and other general corporate purposes.

June 23, 2022

Blood grouping, typing market estimated at $945 million

The overall market is expected to stabilize in 2022 and grow at a 1% compound annual growth rate (CAGR) through 2026 when revenues could reach $1 billion, according to the report, which is published by Kalorama Information, a sister publication of LabPulse.com.

June 16, 2022

PerkinElmer, Novartis expand newborn screening for SCD

In collaboration with the Novartis Africa Sickle Cell Disease program, PerkinElmer aims to expand advocacy efforts to educate patients, caregivers, and communities about the importance of newborn screening and early intervention with hydroxyurea and other SCD treatments.

June 15, 2022

FDA clears Scopio Labs hematology analysis platform

Tel Aviv, Israel-based Scopio said the X100HT is a full-field digital imaging and artificial intelligence (AI)-enabled platform that combines high throughput with high resolution for hematological analysis.

June 9, 2022

SeekIn receives CE Mark for karyotyping kit

Designed to show copy number alteration patterns in leukemia patients based on shallow whole-genome sequencing, the test can help hematologists make diagnoses and prognostic decisions based on European Leukemia Net, Revised International Prognostic Scoring System, or Revised International Staging System guidelines, according to the vendor.

April 6, 2022

PixCell signs MakGroup as distributor for the UAE

Dubai-based MakGroup will have exclusive distribution rights in the UAE for HemoScreen, a five-part, differential complete blood count analyzer that can provide results in five minutes, according to PixCell.

April 6, 2022

Revenues from coagulation lab and POC tests near $4B in 2021

Hemostasis (coagulation) is a complex process in which multiple enzymes and proteins regulate blood flow and clot formation. Coagulation (clot formation), fibrinolysis (the breakup of blood clots), and platelet aggregation are a part of this process.

February 15, 2022

Previous Page

Page 2 of 7

Next Page